

## Correction to LC-MS/MS Method for Simultaneous Determination on a Dried Blood Spot of Multiple Analytes Relevant for Treatment Monitoring in Patients with Tyrosinemia Type I

Giancarlo la Marca,\* Sabrina Malvagia, Serena Materazzi, Maria Luisa Della Bona, Sara Boenzi, Diego Martinelli, and Carlo Dionisi-Vici

*Anal. Chem.* **2012**, *84* (2), 1184–1188. DOI: 10.1021/ac202695h

The authors note that in the “Sample Preparation” section a very important reagent was missing. The Sample Preparation section should be as follows.

**Sample Preparation.** Blood spots were kept in sealed plastic bags at 4 °C with desiccant until analysis. A 3.2 mm diameter disk was punched out from each DBS on the filter paper (903, Whatman GmbH, Dassel Germany) and extracted by addition of 0.2 mL of acetonitrile/water (70:30, v/v), 0.05% formic acid, and 1 mM hydrazine hydrate, containing the internal standards for tyrosine ( $^{13}\text{C}_6$ -Tyr, 5  $\mu\text{mol/L}$ ), methionine ( $^2\text{H}_3$ -Met, 5  $\mu\text{mol/L}$ ), phenylalanine ( $^{13}\text{C}_6$ -Phe, 5  $\mu\text{mol/L}$ ), and succinylacetone ( $^{13}\text{C}_4$ -SUAC, 0.1  $\mu\text{mol/L}$ ). Samples were put in an orbital shaker and kept at 37 °C for 25 min. The succinylacetone was extracted from DBS as a hydrazone derivative. The pooled samples were spiked with varying levels of target markers and used to perform the analytical method validation.

We tested 15 DBS from 6 patients with confirmed Tyrosinemia type I whom NTBC was administered. The age of patients ranged from 6 days to 15 years. The dose of NTBC was 1 mg/kg twice daily. The entire procedure was approved by the Ethical Committee of the Bambino Gesù Hospital and the patients' parents have signed an informed consent.

Published: September 30, 2014